Juan C Sanz1, Martín L Vargas2, Juan J Marín1. 1. 1Psychology Unit, Psychiatric Hospital of Mérida, Mérida, Spain. 2. 2Department of Psychiatry, Complejo Asistencial de Zamora, Zamora, Spain.
Abstract
OBJECTIVES: The aims of this study were to research the following issues in a Spanish population of patients with schizophrenia. (a) The sensitivity and reliability of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to detect cognitive impairment in schizophrenia. (b) The convergent validity of RBANS on a larger battery of neuropsychological tests sensitive to the cognition disorders typically observed in schizophrenia. (c) The correlates of poor performance in RBANS with clinical features and illness severity. METHOD: Thirty schizophrenia patients, 30 non-psychotic patients and 30 healthy participants were assessed using RBANS (form A). We administered a battery of neuropsychological tests and four scales to evaluate patient's clinical status. RESULTS: Schizophrenia patients and non-psychotic patients performed significantly worse than healthy controls on RBANS, and schizophrenia patients performed slightly worse than non-psychiatric controls, but this difference was not significant. Good inter-test reliability and concurrent validity were found. Only a moderate correlation between RBANS performance and illness severity was observed. CONCLUSIONS: RBANS revealed coherence in identifying cognitive impairment in schizophrenia patients of a different cultural background, and it is shown to be a sensitive, valid and easy-to-perform tool for the neuropsychological assessment of Spanish patients with schizophrenia.
OBJECTIVES: The aims of this study were to research the following issues in a Spanish population of patients with schizophrenia. (a) The sensitivity and reliability of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to detect cognitive impairment in schizophrenia. (b) The convergent validity of RBANS on a larger battery of neuropsychological tests sensitive to the cognition disorders typically observed in schizophrenia. (c) The correlates of poor performance in RBANS with clinical features and illness severity. METHOD: Thirty schizophreniapatients, 30 non-psychoticpatients and 30 healthy participants were assessed using RBANS (form A). We administered a battery of neuropsychological tests and four scales to evaluate patient's clinical status. RESULTS:Schizophreniapatients and non-psychoticpatients performed significantly worse than healthy controls on RBANS, and schizophreniapatients performed slightly worse than non-psychiatric controls, but this difference was not significant. Good inter-test reliability and concurrent validity were found. Only a moderate correlation between RBANS performance and illness severity was observed. CONCLUSIONS: RBANS revealed coherence in identifying cognitive impairment in schizophreniapatients of a different cultural background, and it is shown to be a sensitive, valid and easy-to-perform tool for the neuropsychological assessment of Spanish patients with schizophrenia.
Authors: James R Hall; Valerie Hobson Balldin; Adriana Gamboa; Melissa L Edwards; Leigh A Johnson; Sid E O'Bryant Journal: Dev Neuropsychol Date: 2017-11-29 Impact factor: 2.253
Authors: Suzanne Forsyth Herling; Ingrid E Greve; Eduard E Vasilevskis; Ingrid Egerod; Camilla Bekker Mortensen; Ann Merete Møller; Helle Svenningsen; Thordis Thomsen Journal: Cochrane Database Syst Rev Date: 2018-11-23
Authors: Gabriel G De la Torre; Sandra Doval; David López-Sanz; Manuel García-Sedeño; Miguel A Ramallo; Macarena Bernal; Sara González-Torre Journal: Brain Sci Date: 2021-03-19